PMID- 33324558
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201217
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - One Single Site Clinical Study: To Evaluate the Safety and Efficacy of 
      Immunotherapy With Autologous Dendritic Cells, Cytokine-Induced Killer Cells in 
      Primary Hepatocellular Carcinoma Patients.
PG  - 581270
LID - 10.3389/fonc.2020.581270 [doi]
LID - 581270
AB  - Dendritic cells (DCs) and cytokine-induced killer (CIK) cells play an important 
      role in the anti-tumor immune response. In this study, we evaluated the clinical 
      effectiveness of DC/CIK-CD24 immunotherapies to primary hepatocellular carcinoma 
      patients who received radical resection. 36 resected primary hepatocellular 
      carcinoma (HCC) patients were enrolled from August 2014 to December 2015. All 
      patients received two or four times of DC/CIK immunotherapy after radical 
      resection. 1-4 years patients' survival rates were evaluated during the 
      follow-up. The 4-year survival rate of patients who received two times of 
      immunotherapy was 47.1%, and the rate of those who received four times of 
      immunotherapies was 52.6%. Compared to baseline, after receiving the DC/CIK-CD24 
      autotransfusion, the serum Treg concentration of the patients decreased, while 
      CD3+, CD4+, CD56+ increased slightly. The adverse effect of immunotherapy was 
      I-II degrees  transient fever and could be tolerable. DC/CIK-CD24 immunotherapy can delay 
      the relapse time.
CI  - Copyright (c) 2020 Xu, Meng, Mu, Sun and Chai.
FAU - Xu, Kaiyue
AU  - Xu K
AD  - Department of Radiation Oncology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Meng, Zhengjie
AU  - Meng Z
AD  - College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, 
      Nanjing, China.
FAU - Mu, Xiaoxin
AU  - Mu X
AD  - Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
AD  - Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, 
      Nanjing, China.
FAU - Sun, Beicheng
AU  - Sun B
AD  - Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing, China.
FAU - Chai, Yi
AU  - Chai Y
AD  - Department of Radiation Oncology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7724106
OTO - NOTNLM
OT  - CD24
OT  - cytokine-induced killer cells
OT  - dendritic cells
OT  - immunotherapy
OT  - primary hepatocellular carcinoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
PMCR- 2020/01/01
CRDT- 2020/12/16 05:37
PHST- 2020/07/08 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/12/16 05:37 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.581270 [doi]
PST - epublish
SO  - Front Oncol. 2020 Nov 25;10:581270. doi: 10.3389/fonc.2020.581270. eCollection 
      2020.